Tuesday, November 8, 2011


CRISIL Research has come out with its report on Apollo Hospitals Enterprise . The research firm has maintained the fundamental grade of 5/5 to the company in its November 4, 2011 report.

Apollo Hospitals Enterprise Ltd’s (Apollo’s) Q2FY12 results were in line with CRISIL Research’s expectations. Revenues grew at a healthy 19.3% y-o-y supported by growth in the healthcare services and pharmacy businesses, while earnings registered a strong growth of 25% y-o-y due to lower interest cost (adjusted for foreign exchange gain/loss). We retain our positive stance on the growth prospects of the healthcare services industry and Apollo’s dominant position in the organised healthcare market. Consequently, we maintain our fundamental grade of 5/5.

Q2FY12 result analysis
• Revenues grew 9.2% q-o-q (up 19.3% y-o-y) to Rs 6,998 mn, supported by healthy growth in the healthcare services and pharmacy businesses. While the healthcare services business grew 9.0% q-o-q (up 17.0% y-o-y) to Rs 4,915 mn, the pharmacy business registered a growth of ~10% q-o-q (up 25% y-o-y) to Rs 2,085 mn.

• EBITDA margin improved by ~60 bps q-o-q to 17.1% (increased 10 bps y-o-y) driven by 40 bps improvement in the healthcare services business’ margin and 60 bps q-o-q growth in the pharmacy vertical’s margin.

• Adjusted PAT grew by 15.1% q-o-q (up 24.9% y-o-y) to Rs 590 mn due to revenue growth and improvement in margins. PAT margin grew 44 bps q-o-q (up 38 bps y-o-y) to 8.4%. EPS for Q2FY12 was Rs 4.5 compared to Rs 3.8 in Q2FY11.


Hi friends,
my favourite stock Apollo hospital is rocking after Q2 is announced.The Apollo Hospitals Group, Asia’s most profitable and trusted healthcare services provider reported its consolidated results for the quarter and half year ended September 30, 2011 according to Indian GAAP.

Revenues grew 20.4% to Rs. 7,848 million compared to Rs. 6,518 million in Q2FY11. EBITDA grew 18.6% to Rs. 1,311 million as against Rs. 1,105 million in Q2FY11. PAT was Rs. 550 million in Q1FY12 vs. Rs. 515 million in Q2FY11. PAT before Forex translation charge was Rs. 583 million vs. Rs. 492 million, growth of 18.5%. Diluted EPS of Rs. 4.00 per share in Q2FY12.

Revenues grew 21.4% to Rs. 15,082 million compared to Rs. 12,428 million in H1FY11. EBITDA grew 19.9% to Rs. 2,508 million as against Rs. 2,091 million in H1FY11. PAT was Rs. 1,096 million vs. Rs. 934 million in H1FY11, growth of 17.4%. PAT before Forex translation charge was Rs. 1,132 million vs. Rs. 932 million, growth of 21.5%. Diluted EPS of Rs. 8.12 per share in H1FY12

Commenting on the group’s performance Dr. Prathap C Reddy, Chairman said, “We are heartened by the continued growth in revenues and earnings in our business. Apollo has always believed in creating new capacities pan India to bridge the huge gap that exists in the Healthcare Infrastructure in India. Our ability to sustain margins despite the addition of new beds and increasing costs due to inflation and high interest rate regime demonstrates the maturity and robustness of our business model.

Healthcare services have exhibited sustained growth due to a focus on key treatment areas through our COE strategy. Introduction of Robotics planned across seven key locations will further heighten our clinical offerings and medical outcomes. The momentum in the Standalone Pharmacy business combined with improving metrics and profitability validates our belief in this business as a value provider and key component of our integrated healthcare model.